Taiga Biotechnologies, Inc. is a privately held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions. Each of the company's core programs derives from Taiga's proprietary technology platform for conditionally immortalized adult hematopoetic stem cells (HSCs). The company’s initial focus includes the discovery and development of fully human therapeutic monoclonal antibodies against difficult protein targets, an immune response enhancer for improving vaccination strategies for infectious diseases and cancer, and the development of a universal donor blood stem cell line for clinical use.

Latest News

April 2012: Co-founder Yosef Refaeli, Ph.D., speaks frankly with Fast Company about challenges facing early-stage biotech startups and how Taiga is overcoming those challenges. Read the article.

June 2011: Margaret Jackson of the Denver Post writes about Taiga Biotechnologies' Red Blood Cell Pharming Program, outlining the medical need and highlighting the benefits of the recent efforts including the ability to grow a universal donor supply of red blood cells. Read the article.

January 2011: Co-founders Dr. Brian Turner and Dr. Yosef Refaeli are interviewed for a recent article in Life Science Leader written by Gail Dutton about the challenges of raising seed capital. Read the article.

Taiga Biotechnologies Awarded Three New NIH SBIR Grants; With Previous Grants, Total SBIR Funding Received is Over $2.1 Million. Press Release

More News